PATENT CLAIM ANALYSIS

Application Number: 16460710
Application Type: Utility
Filing Date: 2019-07
Publication Date: 2019-10
Patent Classification: ["424", "085200"]

Abstract:
Disclosed is a compound of formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7  and R 8  are as defined in the present application.

Claim (Index 23):
A method for treating a disease or condition mediated by PDE4 enzyme, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I), a stereoisomer, an enantiomer or a tautomer, or a mixture of stereoisomer thereof, a pharmaceutically acceptable salt thereof, a polymorph thereof, a solvate thereof, or a prodrug thereof: wherein,\n R 1  and R 2  are each independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkoxy, hydroxy, cyano, nitro and optionally substituted NR 6 R 7 ; \n R 3  is selected from the group consisting of hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkyl(alkylene)oxy, optionally substituted aryl, optionally substituted aryl(alkylene)oxy and optionally substituted NR 6 R 7 ; \n R 4  and R 5  are each independently selected from the group consisting of hydrogen, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylthio, cyano, optionally substituted cycloalkyl, optionally substituted (alkylene)cycloalkyl, optionally substituted cycloalkyl(alkylene)oxy, optionally substituted cycloalkyloxy, optionally substituted aryl, optionally substituted aryloxy and optionally substituted aryl(alkylene)oxy; \n R 6  and R 7  are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted C(O)R 8  and optionally substituted SO 2 R 8 , or R 6  and R 7  together represent optionally substituted 1,4-butylidene, optionally substituted 1,5-pentylidene, optionally substituted 1,6-hexylidene or optionally substituted CH 2 CH 2 XCH 2 CH 2 , wherein X is selected from the group consisting of O, S and NR 8 ; \n R 8  is selected from the group consisting of hydrogen and optionally substituted alkyl; \n wherein the disease or condition is selected from the group consisting of septic shock, pyaemia, endotoxin shock, blood dynamic shock, septic disease syndrome, ischemia reperfusion injury, cachexia, and graft rejection of graft versus host disease.

Metadata:
- Claim Count in Document: 98.0
- Percentile: 100.0
- Lexical Diversity: 1.44828
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14281289', '15468990', '13320533', '11636903', '11651848']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.779701424850236
- 35 USC 102 Novelty (BERT): 0.6460203662887049
- Combined Prediction Score: 0.7663333189940829
- Mean Citation Score: 489.216516
- Max Citation Score: 605.6618
- Similarity Product: 601.9454230002166

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test